Company intelligence / Profile preview

Antikor Biopharma Limited

Stevenage, Northamptonshire, United Kingdomantikor.co.uk ↗

Ownership: Private
Employees: ~11
Development stage: Preclinical

Overview

Antikor's FDCs have demonstrated superior tumor penetration and rapid elimination from normal tissues in preclinical studies. Their lead product ANT-043 has shown more rapid and complete tumor regression compared with trastuzumab-based ADCs in human gastric cancer pre-clinical models, while being better tolerated[10].

Therapeutic areas: Oncology
Modalities: Antibody Fragment Drug Conjugates (FDCs)
Industry: Biotech

Drug pipeline

2 assets

ANT043

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Essex Bio-Technology Limited

Beyond the preview

Go deeper on Antikor Biopharma Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antikor Biopharma Limited.

Explore the full profile